Pharmacokinetics and Nephrotoxicity of Polymyxin MRX-8 in Rats: A Novel Agent Against Resistant Gram-Negative Bacteria

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2024 Apr 26

PMID 38667030

Authors

Xingyi Qu

Chenxue Guo

Shaojun Liu

Xin Li

Lin Xi

Xiaofen Liu

Jing Zhang

Affiliations

Soon will be listed here.

Abstract

MRX-8 is a novel polymyxin for carbapenem-resistant Gram-negative infections that has been recently evaluated in Phase I clinical trials. Herein, its pharmacokinetics (PK) and nephrotoxicity in rats are reported for the first time. This study aimed at pre-clinical PK and safety assessments. An LC-MS/MS method was developed to determine concentrations of MRX-8 and its major deacylation metabolite, MRX-8039, in rat plasma. Animals were administered a single dose of MRX-8 (2, 4, 6, and 8 mg/kg) or comparator polymyxin B (PMB) (4 and 8 mg/kg) to compare the kidney injury known for the polymyxin drug class. Nephrotoxicity was evaluated using serum creatinine, blood urea nitrogen (BUN) biomarkers, and renal histopathology. In rats, MRX-8 displayed linear PK within the range of 2-8 mg/kg, with approximately 4% of MRX-8 converted to MRX-8039. MRX-8 induced only mild increases in serum creatinine and BUN levels, with an apparent decrease in nephrotoxicity within 24 h, in contrast to PMB, which exhibited a significant and more persistent toxicity. Additional nephrotoxicity biomarkers (plasma NGAL and urinary NGAL, KIM-1, and TIMP-1) have confirmed attenuated MRX-8 kidney injury. Histopathology has revealed significantly greater cellular/tissue toxicity for PMB as compared to MRX-8 (variances of = 0.008 and = 0.048 vs. saline control, respectively). Thus, MRX-8 induces a mild and reversible kidney injury in rats compared to PMB. These data support a continued evaluation of the novel polymyxin in human trials.

Citing Articles

Antibacterials with Novel Chemical Scaffolds in Clinical Development.

Heimann D, Kohnhauser D, Kohnhauser A, Bronstrup M Drugs. 2025; 85(3):293-323.

PMID: 39847315 PMC: 11891108. DOI: 10.1007/s40265-024-02137-x.

References

Sun W, Hu B, Zhang X, Wang Y, Xiang Z, Lin G . Effect of Different Dosage Frequency of Polymyxin B on Rat Nephrotoxicity. Drug Des Devel Ther. 2021; 15:611-616. PMC: 7896728. DOI: 10.2147/DDDT.S287332. View

Richter W, Jacobsen B . Subcutaneous absorption of biotherapeutics: knowns and unknowns. Drug Metab Dispos. 2014; 42(11):1881-9. DOI: 10.1124/dmd.114.059238. View

Vardakas K, Falagas M . Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis. Int J Antimicrob Agents. 2016; 49(2):233-238. DOI: 10.1016/j.ijantimicag.2016.07.023. View

Schrezenmeier E, Barasch J, Budde K, Westhoff T, Schmidt-Ott K . Biomarkers in acute kidney injury - pathophysiological basis and clinical performance. Acta Physiol (Oxf). 2016; 219(3):554-572. PMC: 5575831. DOI: 10.1111/apha.12764. View

Schmidt-Ott K . Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury--where do we stand today?. Nephrol Dial Transplant. 2011; 26(3):762-4. DOI: 10.1093/ndt/gfr006. View

Beal S . Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2002; 28(5):481-504. DOI: 10.1023/a:1012299115260. View

Jean S, Gould I, Lee W, Hsueh P . New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship. Drugs. 2019; 79(7):705-714. DOI: 10.1007/s40265-019-01112-1. View

Lepak A, Wang W, Andes D . Pharmacodynamic Evaluation of MRX-8, a Novel Polymyxin, in the Neutropenic Mouse Thigh and Lung Infection Models against Gram-Negative Pathogens. Antimicrob Agents Chemother. 2020; 64(11). PMC: 7577140. DOI: 10.1128/AAC.01517-20. View

Zavascki A, Nation R . Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?. Antimicrob Agents Chemother. 2016; 61(3). PMC: 5328560. DOI: 10.1128/AAC.02319-16. View

10.

Cheah S, Bulitta J, Li J, Nation R . Development and validation of a liquid chromatography-mass spectrometry assay for polymyxin B in bacterial growth media. J Pharm Biomed Anal. 2014; 92:177-82. PMC: 3967869. DOI: 10.1016/j.jpba.2014.01.015. View

11.

Wu S, Yin D, Zhi P, Guo Y, Yang Y, Zhu D . Activity of MRX-8 and Comparators Against Clinical Isolated Gram-Negative Bacilli in China. Front Cell Infect Microbiol. 2022; 12:829592. PMC: 9135056. DOI: 10.3389/fcimb.2022.829592. View

12.

Mariano F, Malvasio V, Risso D, Depetris N, Pensa A, Fucale G . Colistin Therapy, Survival and Renal Replacement Therapy in Burn Patients: A 10-Year Single-Center Cohort Study. Int J Gen Med. 2022; 15:5211-5221. PMC: 9150021. DOI: 10.2147/IJGM.S357427. View

13.

Zhan Y, Ma N, Liu R, Wang N, Zhang T, He L . Polymyxin B and polymyxin E induce anaphylactoid response through mediation of Mas-related G protein-coupled receptor X2. Chem Biol Interact. 2019; 308:304-311. DOI: 10.1016/j.cbi.2019.05.014. View

14.

Lakeev A, Yanovskaya E, Yanovsky V, Andropov M, Frelikh G, Chukicheva I . LC-MS/MS method for the determination of a semi-synthetic phenolic antioxidant 2,6-diisobornyl-4-methylphenol in rats after different administration routes. J Chromatogr B Analyt Technol Biomed Life Sci. 2022; 1213:123537. DOI: 10.1016/j.jchromb.2022.123537. View

15.

Abdelraouf K, He J, Ledesma K, Hu M, Tam V . Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrob Agents Chemother. 2012; 56(11):5724-7. PMC: 3486600. DOI: 10.1128/AAC.01333-12. View

16.

Nang S, Azad M, Velkov T, Zhou Q, Li J . Rescuing the Last-Line Polymyxins: Achievements and Challenges. Pharmacol Rev. 2021; 73(2):679-728. PMC: 7911091. DOI: 10.1124/pharmrev.120.000020. View

17.

Lodise T, Yucel E, Obi E, Watanabe A, Nathanson B . Incidence of acute kidney injury (AKI) and its impact on patient outcomes among adult hospitalized patients with carbapenem-resistant Gram-negative infections who received targeted treatment with a newer β-lactam or β-lactam/β-lactamase inhibitor-,.... J Antimicrob Chemother. 2023; 79(1):82-95. PMC: 10761276. DOI: 10.1093/jac/dkad351. View

18.

Yu M, Li H, Wang B, Wu Z, Wu S, Jiang G . Baicalein ameliorates polymyxin B-induced acute renal injury by inhibiting ferroptosis via regulation of SIRT1/p53 acetylation. Chem Biol Interact. 2023; 382:110607. DOI: 10.1016/j.cbi.2023.110607. View

19.

Wagenlehner F, Lucenteforte E, Pea F, Soriano A, Tavoschi L, Steele V . Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. Clin Microbiol Infect. 2020; . DOI: 10.1016/j.cmi.2020.12.009. View

20.

Hvidberg V, Jacobsen C, Strong R, Cowland J, Moestrup S, Borregaard N . The endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and mediates its cellular uptake. FEBS Lett. 2005; 579(3):773-7. DOI: 10.1016/j.febslet.2004.12.031. View